Oryzon Genomics SA, of Barcelona, reported that its R&D collaboration with Roche AG, of Basel, Switzerland, around ORY-1001, licensed to Roche in 2014, has been extended until March 2017 with the goal of finalizing technology and knowledge transfer between the companies.